1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. EC Healthcare
  6. News
  7. Summary
    2138   KYG3037S1021


Delayed Hong Kong Stock Exchange  -  04:08 2022-08-10 am EDT
6.450 HKD   -4.87%
08/01EC Healthcare Grants Share Options to Three Employees
07/31EC Healthcare Closes $32 Million Share Subscription in JV Company
07/27New entries in the Asia Investor portfolio
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EC Healthcare Opens New Multi-Service Flagship Medical Centre at Central and Advanced Imaging Centre at Taikoo

04/04/2022 | 12:36am EDT

HONG KONG, Apr 4, 2022 - (ACN Newswire) - - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's new multi-service flagship medical centre ("New Flagship Centre") located in Central and its new advanced imaging centre located in Tai Koo have commenced operations on 31 March 2022 and 1 April 2022 respectively, thus further expanding the Group's market share in the medical market.

The New Flagship Centre is located at Fung House in Central, Hong Kong Island, with seven new floors with an aggregate gross floor area of approximately 22,000 square feet. The upper five floors of the New Flagship Centre offer services including but not limited to general medical, orthopedics, ophthalmology, chiropractic, physiotherapy and pain management and service centres have commenced operations. The other two floors will be an advanced imaging centre serving as a one-stop medical imaging service hub, which is expected to commence operation in the fourth quarter of 2022.

In addition, the gross floor area of another new advanced imaging centre is located on 6/F of Cityplaza in Tai Koo, Hong Kong Island is approximately 3,400 square feet. After this expansion, the Group operates six advanced imaging centres across the New Territories, Kowloon and Hong Kong Island, thereby further improving its service network.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "EC Healthcare has been developing preventive and precision medicine as its core businesses. To fulfill the strong demand for medical services, the Group has established the related service centres through organic growth in an effort to further exploit business synergy among its diversified medical and healthcare businesses. The Group will remain committed to building up an enclosed healthcare ecosystem focused on satisfaction of customers in order to provide quality one-stop services to the customers and consolidate the Group's industry leadership as a one-stop comprehensive healthcare and medical service provider."

About EC Healthcare

EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:

iPR Ogilvy Limited

Callis Lau / Lorraine Luk / Charmaine Ip

Tel: (852) 2136 6952 / 2169 0467 / 3920 7649

Fax: (852) 3170 6606

Email: ech@iprogilvy.com

Copyright 2022 ACN Newswire . All rights reserved.

© Japan Corporate News, source JCN Press Releases

All news about EC HEALTHCARE
08/01EC Healthcare Grants Share Options to Three Employees
07/31EC Healthcare Closes $32 Million Share Subscription in JV Company
07/27New entries in the Asia Investor portfolio
07/27EC HEALTHCARE : appoints Chief Operating Officer, Chief Public Affairs Officer & Chief Den..
07/26EC Healthcare's Q2 Sales Jumps 17%
07/25EC Healthcare Proposes Final Dividend for the Year Ended 31 March 2022
07/25EC Healthcare expects sales volume to increase no less than 17% Y-o-Y to no less than H..
07/25EC Healthcare Announces Sales Guidance for the Quarter of April to June 2022
07/25EC Healthcare Opens Two New Service Points in Shenzhen
07/18EC Healthcare Provides Healthcare Services for Signature and Prestige Banking Customers..
More news
Sales 2023 3 668 M 467 M 467 M
Net income 2023 365 M 46,5 M 46,5 M
Net cash 2023 418 M 53,2 M 53,2 M
P/E ratio 2023 24,0x
Yield 2023 3,07%
Capitalization 7 601 M 968 M 968 M
EV / Sales 2023 1,96x
EV / Sales 2024 1,56x
Nbr of Employees 2 674
Free-Float 35,7%
Duration : Period :
EC Healthcare Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EC HEALTHCARE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 7
Last Close Price 6,78 HKD
Average target price 11,53 HKD
Spread / Average Target 70,1%
EPS Revisions
Managers and Directors
Lyn Wade Lu Co-Chief Executive Officer & Executive Director
Chi Fai Tang Chairman & Co-Chief Executive Officer
Heung Wing Lee Finance Director
Kun Shing Luk Non-Executive Director & Chief Information Officer
Ka Ki Wong Executive Director & Chief Investment Officer
Sector and Competitors